interferon ms | Interferons in the Treatment of Multiple Sclerosis

Keyword	CPC	PCC	Volume	Score	Length of keyword
interferon ms	0.68	0.8	3322	36	13
interferon	0.34	0.6	1885	75	10
ms	1.89	0.8	3588	40	2

Keyword	CPC	PCC	Volume	Score
interferon ms	0.87	1	1640	40
interferon ms treatment side effects	1.49	0.4	1491	5
interferon ms treatment	0.26	0.3	5336	21
interferon msc proliferation	0.79	0.6	209	8
interferon ms drugs	1.62	0.3	9981	73
define the medical term synthetic interferon	0.37	1	417	24
the latest research on interferon and ms	1.51	0.8	5841	53
beta interferon ms	1.42	0.2	7273	91
interferon treatment side effects	0.02	0.9	9402	12
interferon therapy side effects	1.38	0.8	5239	8
interferon medication side effects	1.21	0.9	8874	13
interferon for ms treatment	0.37	0.5	9372	88
side effects of interferon	0.59	0.3	143	41
interferon cancer treatment side effects	0.57	0.9	9772	31
effects of interferon treatment	0.63	0.9	968	77
adverse effects of interferon therapy	1.03	0.2	7999	54
long term side effects of interferon therapy	1.68	0.1	457	12
interferon injection for ms	1.66	0.1	4686	93
interferon therapy for ms	0.83	1	8247	99
interferon permanent side effects	1.02	0.5	3582	59
long term side effects of interferon	1.97	0.4	354	29
how does interferon work for ms	1.65	0.4	4343	8
interferon medication for ms	1.74	0.7	5777	39
interferon treatment for multiple sclerosis	1.74	0.4	4655	63
interferon and multiple sclerosis	0.57	0.9	139	77

Search Results related to interferon ms on Search Engine

Interferons in the Treatment of Multiple Sclerosis - PMC
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446632/

WEBOct 30, 2019 · Summary. Even with the wide array of DMTs currently available, IFNβ therapy still plays an important role in the treatment of patients with MS. Interferons have been shown to improve clinical outcomes, and their long-term safety profiles make them standard-of-care, first-line therapy for MS.

DA: 62 PA: 91 MOZ Rank: 26

Beta interferons as immunotherapy in multiple sclerosis: a new …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928608/

WEBBeta interferons (IFN-β) are pleiotropic cytokines with antiviral properties. They play important roles in the pathogenesis of multiple sclerosis (MS), an incurable immune-mediated disorder of the central nervous system.

DA: 6 PA: 79 MOZ Rank: 9

Interferons and Multiple Sclerosis: Lessons from 25 Years of …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258741/

WEBJul 6, 2021 · Key Points. Since 1981, clinical and real-world observational studies have demonstrated the effectiveness of interferon therapies in reducing relapse rate, disability worsening/progression, and the number of new or newly enlarging lesions in patients with multiple sclerosis (MS).

DA: 58 PA: 91 MOZ Rank: 64

Interferon Beta Drugs for Multiple Sclerosis - WebMD
webmd.com

https://www.webmd.com/multiple-sclerosis/interferon-beta-drugs-for-multiple-sclerosis

WEBMar 6, 2024 · Your body makes interferons. A man-made version of them can treat multiple sclerosis (MS), especially interferon betas. Learn about when doctors use them, how well they work, their...

DA: 87 PA: 51 MOZ Rank: 92

Interferons in the Treatment of Multiple Sclerosis: A Clinical Efficacy
nih.gov

https://pubmed.ncbi.nlm.nih.gov/32863784/

WEBInterferon beta (IFNβ) was the first disease-modifying therapy available to treat multiple sclerosis (MS), providing patients with a treatment that resulted in reduced relapse rates and delays in the onset of disability. Four IFNβ drugs are currently approved to treat relapsing forms of MS: subcutan …

DA: 93 PA: 94 MOZ Rank: 12

Interferon-β mechanisms of action in multiple sclerosis
neurology.org

https://www.neurology.org/doi/10.1212/wnl.0b013e3181c97d99

WEBDec 28, 2009 · Interferon-β mechanisms of action in multiple sclerosis | Neurology. The most widely read and highly cited peer-reviewed neurology journal. Articles. December 28, 2009. Interferon-β mechanisms of action in multiple sclerosis. Suhayl Dhib-Jalbut, MD, and Steven Marks Authors Info & Affiliations. January 5, 2010 issue. 74 …

DA: 88 PA: 5 MOZ Rank: 47

Intramuscular Interferon Beta-1A Therapy Initiated during a First
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJM200009283431301

WEBSep 28, 2000 · Interferon-beta has demonstrated benefits in the treatment of patients with established multiple sclerosis, including slowing the progression of physical disability, 9,10 reducing the rate...

DA: 52 PA: 3 MOZ Rank: 55

Beta interferons | MS Society
mssociety.org.uk

https://www.mssociety.org.uk/about-ms/treatments-and-therapies/disease-modifying-therapies/beta-interferons

WEBBeta interferons | MS Society. Beta interferons are disease modifying therapies (DMTs) for relapsing MS and in some cases secondary progressive MS. Their brand names are Avonex, Betaferon, Extavia, Plegridy, Rebif and they are all taken as injections. Read the latest information about DMTs and coronavirus COVID-19. Jump to:

DA: 82 PA: 9 MOZ Rank: 12

Multiple sclerosis - Diagnosis and treatment - Mayo Clinic
mayoclinic.org

https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/diagnosis-treatment/drc-20350274

WEBDec 24, 2022 · Treatment. There is no cure for multiple sclerosis. Treatment typically focuses on speeding recovery from attacks, reducing new radiographic and clinical relapses, slowing the progression of the disease, and managing MS symptoms. Some people have such mild symptoms that no treatment is necessary.

DA: 75 PA: 97 MOZ Rank: 40

Emerging treatments for multiple sclerosis - Mayo Clinic
mayoclinic.org

https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/expert-answers/emerging-treatments-for-ms/faq-20096786

WEBJul 14, 2022 · The dosing of interferon varies depending on which drug is used. Glatiramer acetate (Copaxone, Glatopa) can reduce relapse rates in multiple sclerosis and has long-term safety data. The monoclonal antibody ofatumumab (Kesimpta, Arzerra), approved by the FDA in 2020, targets cells that damage the nervous system.

DA: 32 PA: 35 MOZ Rank: 87